Pictet Asset Management Holding Sa Biotechnology

Pictet Asset Management Holding Sa

$86.3 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRTX Vertex Pharmaceuticals Inc	$114B	$321 Million 0.37% of portfolio	661,187	Q1 2025 Added 27.23%
REGN Regeneron Pharmaceuticals, Inc.	$52.6B	$191 Million 0.22% of portfolio	300,956	Q1 2025 Added 40.57%
INSM Insmed Inc	$9.45B	$154 Million 0.18% of portfolio	2,013,329	Q1 2025 Added 2.74%
ARGX Argenx Se	$32.3B	$136 Million 0.16% of portfolio	229,441	Q1 2025 Reduced 19.41%
ALNY Alnylam Pharmaceuticals, Inc.	$37.7B	$130 Million 0.15% of portfolio	480,967	Q1 2025 Added 11.69%
TGTX Tg Therapeutics, Inc.	$5.1B	$94.5 Million 0.11% of portfolio	2,397,184	Q1 2025 Reduced 14.2%
BPMC Blueprint Medicines Corp	$7.63B	$84.5 Million 0.1% of portfolio	954,596	Q1 2025 Reduced 19.35%
CYTK Cytokinetics Inc	$2.94B	$78.6 Million 0.09% of portfolio	1,956,327	Q1 2025 Added 2.32%
SWTX Spring Works Therapeutics, Inc.	$2.91B	$73.7 Million 0.09% of portfolio	1,670,008	Q1 2025 Reduced 30.17%
INCY Incyte Corp	$14.5B	$73.2 Million 0.08% of portfolio	1,209,609	Q1 2025 Reduced 7.94%
BBIO Bridge Bio Pharma, Inc.	$5.08B	$72.3 Million 0.08% of portfolio	2,090,268	Q1 2025 Added 15.65%
MDGL Madrigal Pharmaceuticals, Inc.	$4.71B	$68.6 Million 0.08% of portfolio	207,043	Q1 2025 Reduced 0.69%
UTHR United Therapeutics Corp	$14.8B	$61.9 Million 0.07% of portfolio	200,657	Q1 2025 Added 69.92%
SRPT Sarepta Therapeutics, Inc.	$3.3B	$59.8 Million 0.07% of portfolio	937,023	Q1 2025 Reduced 10.42%
PTCT Ptc Therapeutics, Inc.	$3.49B	$53.1 Million 0.06% of portfolio	1,042,458	Q1 2025 Added 41.56%
SMMT Summit Therapeutics Inc.	$3.67B	$51.3 Million 0.06% of portfolio	2,661,604	Q1 2025 Added 91.86%
RARE Ultragenyx Pharmaceutical Inc.	$2.53B	$51 Million 0.06% of portfolio	1,409,199	Q1 2025 Added 20.07%
XENE Xenon Pharmaceuticals Inc.	$1.8B	$49.6 Million 0.06% of portfolio	1,477,617	Q1 2025 Reduced 1.26%
VKTX Viking Therapeutics, Inc.	$2.06B	$46.4 Million 0.05% of portfolio	1,921,436	Q1 2025 Added 55.32%
VRNA Verona Pharma PLC	$4.95B	$44.6 Million 0.05% of portfolio	703,063	Q1 2025 New
MRUS Merus N.V.	$2.57B	$43.4 Million 0.05% of portfolio	1,032,101	Q1 2025 Added 0.03%
PCVX Vaxcyte, Inc.	$2.08B	$39.7 Million 0.05% of portfolio	1,050,678	Q1 2025 Added 3.23%
NUVL Nuvalent, Inc.	$3.21B	$39.3 Million 0.05% of portfolio	554,141	Q1 2025 Reduced 13.66%
AXSM Axsome Therapeutics, Inc.	$4.51B	$38.9 Million 0.05% of portfolio	333,205	Q1 2025 Added 7,022.81%
CRNX Crinetics Pharmaceuticals, Inc.	$1.71B	$35.1 Million 0.04% of portfolio	1,047,015	Q1 2025 Added 23.46%
MIRM Mirum Pharmaceuticals, Inc.	$1.63B	$35.1 Million 0.04% of portfolio	778,244	Q1 2025 Reduced 9.52%
IMVT Immunovant, Inc.	$3.55B	$32.7 Million 0.04% of portfolio	1,188,578	Q1 2025 Added 1.1%
ETNB 89bio, Inc.	$457M	$30.6 Million 0.04% of portfolio	4,204,887	Q1 2025 Added 39.84%
IDYA Ideaya Biosciences, Inc.	$956M	$30.1 Million 0.03% of portfolio	1,838,764	Q1 2025 Reduced 5.28%
DAWN Day One Biopharmaceuticals, Inc.	$469M	$28.8 Million 0.03% of portfolio	3,635,580	Q1 2025 Added 4.17%
RVMD Revolution Medicines, Inc.	$3.46B	$26.4 Million 0.03% of portfolio	747,560	Q1 2025 Added 4.91%
JAZZ Jazz Pharmaceuticals PLC	$6.79B	$25.8 Million 0.03% of portfolio	207,640	Q1 2025 Reduced 1.93%
RNA Avidity Biosciences, Inc.	$1.61B	$25.8 Million 0.03% of portfolio	873,222	Q1 2025 Added 9.29%
NRIX Nurix Therapeutics, Inc.	$501M	$20.8 Million 0.02% of portfolio	1,754,280	Q1 2025 Reduced 0.83%
EXEL Exelixis, Inc.	$13.8B	$20.8 Million 0.02% of portfolio	563,476	Q1 2025 Reduced 31.39%
VERA Vera Therapeutics, Inc.	$512M	$20.2 Million 0.02% of portfolio	840,258	Q1 2025 Reduced 0.13%
BMRN Biomarin Pharmaceutical Inc	$10.6B	$20.2 Million 0.02% of portfolio	285,300	Q1 2025 Added 0.21%
MRNA Moderna, Inc.	$10.6B	$19.3 Million 0.02% of portfolio	679,748	Q1 2025 Reduced 61.52%
IONS Ionis Pharmaceuticals Inc	$4.84B	$18.7 Million 0.02% of portfolio	618,550	Q1 2025 Reduced 0.36%
JANX Janux Therapeutics, Inc.	$992M	$17.7 Million 0.02% of portfolio	656,605	Q1 2025 Added 70.64%
CLDX Celldex Therapeutics, Inc.	$925M	$17.4 Million 0.02% of portfolio	957,794	Q1 2025 Reduced 12.14%
VRDN Viridian Therapeutics, Inc.\De	$555M	$16.8 Million 0.02% of portfolio	1,248,721	Q4 2024 Added 21.79%
ASND Ascendis Pharma A/S	$9.81B	$16.6 Million 0.02% of portfolio	106,758	Q1 2025 Reduced 25.96%
PTGX Protagonist Therapeutics, Inc	$2.33B	$14.3 Million 0.02% of portfolio	295,593	Q1 2025 Reduced 0.31%
RYTM Rhythm Pharmaceuticals, Inc.	$3.42B	$13.7 Million 0.02% of portfolio	259,346	Q1 2025 Reduced 30.91%
FOLD Amicus Therapeutics, Inc.	$1.73B	$13.3 Million 0.02% of portfolio	1,628,213	Q1 2025 Added 7.29%
AKRO Akero Therapeutics, Inc.	$2.3B	$12.7 Million 0.01% of portfolio	314,711	Q1 2025 New
MLTX Moon Lake Immunotherapeutics	$1.44B	$12.6 Million 0.01% of portfolio	322,114	Q1 2025 Reduced 7.07%
TVTX Travere Therapeutics, Inc.	$964M	$11.9 Million 0.01% of portfolio	665,570	Q1 2025 Reduced 6.18%
KRYS Krystal Biotech, Inc.	$3.23B	$11.8 Million 0.01% of portfolio	65,262	Q1 2025 Reduced 41.78%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pictet Asset Management Holding Sa, based on Form 13F filings with the SEC.

News

Stay updated on Pictet Asset Management Holding Sa with notifications on news.